Trials / Completed
CompletedNCT01102387
Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections
Phase IIa, Two-centre, Randomized, Double Blind Study to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS41003 Versus Corresponding Mono-substances in Patients With Candida Infections in Intertriginous Areas at the Trunk
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine the efficacy and safety of once daily topical application of the combinational cream LAS41003 compared to the corresponding mono-substances in the treatment of candida infections in intertriginous areas at the trunk.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LAS41003 | Once daily, topically |
| DRUG | LAS189962 | Once daily, topically |
| DRUG | LAS189961 | Once daily, topically |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-04-13
- Last updated
- 2012-07-04
Locations
6 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01102387. Inclusion in this directory is not an endorsement.